跳转至内容
Merck

1719000

USP

华法林

United States Pharmacopeia (USP) Reference Standard

别名:

4-羟基-3-(3-氧代-1-苯基丁基)-2H-1-苯并吡喃-2-酮, 杀鼠灵钠

登录查看公司和协议定价


About This Item

经验公式(希尔记法):
C19H16O4
CAS号:
分子量:
308.33
Beilstein:
8868198
MDL號碼:
分類程式碼代碼:
41116107
PubChem物質ID:
NACRES:
NA.24
价格与库存信息目前不能提供

等級

pharmaceutical primary standard

API 家族

warfarin

製造商/商標名

USP

mp

162-164 °C (lit.)

應用

pharmaceutical (small molecule)

形式

neat

儲存溫度

2-8°C

SMILES 字串

CC(=O)CC(c1ccccc1)C2=C(O)c3ccccc3OC2=O

InChI

1S/C19H16O4/c1-12(20)11-15(13-7-3-2-4-8-13)17-18(21)14-9-5-6-10-16(14)23-19(17)22/h2-10,15,21H,11H2,1H3

InChI 密鑰

PJVWKTKQMONHTI-UHFFFAOYSA-N

基因資訊

human ... VKORC1(79001)

正在寻找类似产品? 访问 产品对比指南

一般說明

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

應用

Warfarin USP Reference standard, intended for use in specified quality tests and assays as specified in the USP compendia. Also, for use with USP monographs such as:
  • Warfarin Sodium
  • Warfarin Sodium Tablets
  • Warfarin Sodium for Injection

分析報告

These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.  ​

其他說明

Sales restrictions may apply.

法律資訊

訊號詞

Danger

危險分類

Acute Tox. 1 Dermal - Acute Tox. 1 Inhalation - Acute Tox. 2 Oral - Aquatic Chronic 2 - Repr. 1A - STOT RE 1 Oral

標靶器官

Blood

儲存類別代碼

6.1A - Combustible acute toxic Cat. 1 and 2 / very toxic hazardous materials

水污染物質分類(WGK)

WGK 3

閃點(°F)

Not applicable

閃點(°C)

Not applicable


历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our 文件 section.

如需帮助,请联系 客户支持

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

其他客户在看

Slide 1 of 4

1 of 4

ACP Journal Club: mechanical left atrial appendage closure was noninferior and superior to warfarin in atrial fibrillation.
Vinai Bhagirath et al.
Annals of internal medicine, 162(8), JC4-JC4 (2015-04-22)
Ye Wang et al.
Cardiovascular drugs and therapy, 28(6), 575-585 (2014-10-17)
This study aimed to evaluate the cost-effectiveness of dabigatran and rivaroxaban compared with warfarin for the prevention of stroke in patients with atrial fibrillation (AF) in Singapore. A Markov model was constructed to compare the lifetime costs, quality-adjusted life-years (QALYs)
Minoru Yabuta et al.
Journal of vascular and interventional radiology : JVIR, 25(9), 1406-1412 (2014-05-24)
To evaluate retrospectively the long-term outcomes of percutaneous transhepatic balloon angioplasty performed for portal vein stenosis (PVS) after pediatric living donor liver transplantation (LDLT). Between October 1997 and December 2013, of 527 pediatric patients (age < 18 y) who underwent
Tomasz Baron et al.
Heart (British Cardiac Society), 101(2), 101-106 (2014-10-22)
We aimed to assess differences in incidence, clinical features, current treatment strategies and outcome in patients with type 2 vs. type 1 acute myocardial infarction (AMI). All 20 138 hospitalisations in Sweden with a diagnosis of AMI registered during 2011 in
Vivek Y Reddy et al.
JAMA, 312(19), 1988-1998 (2014-11-17)
While effective in preventing stroke in patients with atrial fibrillation (AF), warfarin is limited by a narrow therapeutic profile, a need for lifelong coagulation monitoring, and multiple drug and diet interactions. To determine whether a local strategy of mechanical left

Questions

Reviews

No rating value

Active Filters

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门